Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Status:
RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.
Phase:
PHASE2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute